Background A reduction of ADA2 activity due to autosomal recessive loss of function
mutations in CECR1 results in a newly described vasculopathic phenotype reminiscent of …

Objective To provide updated guidelines for pharmacologic management of juvenile
idiopathic arthritis (JIA), focusing on treatment of oligoarthritis, temporomandibular joint (TMJ) …

Objective: To assess the utility and safety of rituximab in pediatric autoimmune and inflammatory
disorders of the CNS. Methods: Multicenter retrospective study. Results: A total of 144 …

Objective: We undertook an observational study to obtain a complete overview of the long-term
effectiveness and safety of etanercept in patients with different juvenile idiopathic arthritis …

OBJECTIVE: To study occurrence as well as clinical signs and symptoms of temporomandibular
joint (TMJ) involvement in juvenile idiopathic arthritis (JIA) in a population representing …

Objective To uniquely classify children with microscopic polyangiitis (MPA), to describe their
demographic characteristics, presenting clinical features, and initial treatments in …

Context Since the introduction of biologic therapies, the pharmacological treatment approach
for juvenile idiopathic arthritis (JIA) has changed substantially, with achievement of inactive …

Background The interleukin‐1 (IL‐1) mediated systemic autoinflammatory diseases, including
the cryopyrin‐ associated periodic syndromes (CAPS), tumour necrosis factor receptor‐…

Objective: To investigate the facioskeletal morphology in patients with juvenile idiopathic
arthritis (JIA) with and without temporomandibular joint (TMJ) involvement. Methods: Eighty five …

Objective To provide recommendations for the management of juvenile idiopathic arthritis (JIA)
with a focus on nonpharmacologic therapies, medication monitoring, immunizations, and …